Journal of International Oncology››2014,Vol. 41››Issue (11): 872-874.doi:10.3760/cma.j.issn.1673-422X.2014.11.022
Previous ArticlesNext Articles
Online:
2014-12-03Published:
2015-01-20Contact:
Wang Hong, Email: qingmeisu6856@163.comWANG Hong. Expressions and significances of sICAM-1 and sCD44v6 in peritoneal lavage fluid after laparoscopically assisted radical gastrectomy[J]. Journal of International Oncology, 2014, 41(11): 872-874.
[1] 罗华星, 余佩武, 王自强, 等. 腹腔镜辅助下胃癌根治术对机体免疫功能的影响[J]. 第三军医大学学报, 2005, 27(9): 910912. [2] 徐晓武, 牟一平, 严加费, 等. 应用腹腔镜辅助D2根治术治疗进展期胃癌的临床观察[J]. 中华医学杂志, 2008, 88(31): 21952197. [3] 王连聪, 郑正葆. CD44v6及其可溶性成分在胃癌中的意义[J]. 中华消化杂志, 2001, 21(8): 495496. [4] Alkhamesi NA, Ziprin P, Pfistermuller K, et al. ICAM1 mediated peritoneal carcinomatosis,a target for therapeutic intervention[J]. Clin Exp Metastas, 2005, 22(6): 449459. [5] Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Clinical significance of serum levels of Eselection,intercullar adhesion molecule1,and vascular cell adhesion molecular1 in gastric cancer patients[J]. Am J Gastroenterol, 2003, 98(2): 478485. [6] 徐惠绵, 陈俊青, 王舒宝. 胃癌的腹膜亚临床转移检测及阻断治疗研究[J]. 中国肿瘤临床, 2002, 29(2):134137. [7] Lessan K, Aguiar DJ, Oegema T, et al. CD44 and betal integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells[J]. Am J Pahtol, 1999, 154(5): 15251537. [8] 赵东晖, 徐惠绵, 孙秀菊, 等. 腹腔液中CD44和整合素β1表达与胃癌腹膜转移的关系[J]. 世界华人消化杂志, 2007, 15(11): 12881291. [9] Jothy S. CD44 and its partners in metastasis[J]. Clin Exp Metastasis, 2003, 20(3): 195201. [10] 丁有成. CD44在腹腔肿瘤腹膜转移中的意义[J]. 国外医学·消化疾病分册,2003, 23(3): 158161. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[8] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[9] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[10] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[11] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[12] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[13] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[14] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[15] | Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun.Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||